Zisty 10 mg


ZISTY 10 mg Lisinpril Tablets USP 10 mg

Zisty is an ACE inhibitors (Angiotensin Converng Enzyme). A potent vasocontrictor this results in lower levels of angiotensin (II) which causes an increase in plasma renin acvity and a reducon in aldosterone secreon. it also prevents the degradaon of bradykinin. It is used in hypertension and in congesve heart failure as an adjuncve treatment with diurecs


Clinical Pharmacology

Mechanism of Action
Lisinopril inhibitors angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin 1 to the vasoconstrictor substance, angiotensin 11. Angiotensin 11 also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin 11 which leads to decreased vasopressor activity and to decrease aldosterone secretion.
The latter decreases may result in a small increase of serum potassium. In hypertension patients with normal renal function treated with Lisinopril alone for up to 24 weeks, the mean increase in serum potassium was approximately 0.1mEq/L: however, approximately 15% of patients had increases greater than 0.5mEq/L and approximately 6% had a decrease greater than 0.5mEq/L.

Products Profile

Download Products Profile



Other Info

Heart failure: During baseline-controlled clinical trials, in patients receiving digitals and diuretics, single doses of Lisinopril resulted in decreases in pulmonary capillary wedge pressure, systemic vascular resistance and blood pressure accompanied by an increase in cardiac output and no change in heart rate.

In tow placebos controlled, 12-week clinical studies using dose of Lisinopril up to 20mg Lisinopril as adjunctive therapy to digitalis and diuretics improved the following signs and symptoms due to congestive heart failure: edema, rales paroxysmal nocturnal dyspnea and jugular distention.
In one of the studies, beneficial response was noted for; presence of third heart sound and the number of patients classified as NHYA Class 111 and 1V. Exercise tolerance was also improved in this study. The one-daily dosing for the treatment of congestive heart failure was the only dosage regimen used during trial development and was determined by the measurement of hemodynamic response. A large (over 3000 patients) survival study, the ATLAST trial, comparing 2.5 and 35mg of lisinopril in patients with heart failure, showed that the higher doses of lisinopril had outcomes at least favorable as the lower dose.